RNF175 抗体 (AA 106-134)
(4 references)Our Local Distributor
北京 101111
Quick Overview for RNF175 抗体 (AA 106-134) (ABIN1881757)
抗原
适用
宿主
克隆类型
标记
应用范围
克隆位点
-
-
抗原表位
- AA 106-134
-
纯化方法
- This antibody is purified through a protein A column, followed by peptide affinity purification.
-
免疫原
- This RNF175 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 106-134 amino acids from the Central region of human RNF175.
-
亚型
- Ig Fraction
-
-
anti-Ring Finger Protein 175 (RNF175) (AA 211-301) antibody
RNF175 适用: 人 ELISA 宿主: 小鼠 Monoclonal 4E9 unconjugated
anti-Ring Finger Protein 175 (RNF175) (AA 58-107) antibodyRNF175 适用: 人 WB 宿主: 兔 Polyclonal unconjugated
anti-Ring Finger Protein 175 (RNF175) antibodyRNF175 适用: 人 WB, ELISA 宿主: 兔 Polyclonal unconjugated
-
-
应用备注
- WB: 1:1000
-
限制
- 仅限研究用
-
-
-
状态
- Liquid
-
缓冲液
- Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.
-
储存液
- Sodium azide
-
注意事项
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
储存条件
- 4 °C,-20 °C
-
有效期
- 6 months
-
-
-
: "Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study." in: Diabetes Care, Vol. 33, Issue 10, pp. 2250-3, (2010) (PubMed).
: "Association between genetic variants in VEGF, ERCC3 and occupational benzene haematotoxicity." in: Occupational and environmental medicine, Vol. 66, Issue 12, pp. 848-53, (2009) (PubMed).
: "Gene-centric association signals for lipids and apolipoproteins identified via the HumanCVD BeadChip. ..." in: American journal of human genetics, Vol. 85, Issue 5, pp. 628-42, (2009) (PubMed).
: "hORFeome v3.1: a resource of human open reading frames representing over 10,000 human genes." in: Genomics, Vol. 89, Issue 3, pp. 307-15, (2007) (PubMed).
-
: "Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study." in: Diabetes Care, Vol. 33, Issue 10, pp. 2250-3, (2010) (PubMed).
-
-
